Monopar Therapeutics (MNPR) Enterprise Value: 2016-2020
Historic Enterprise Value for Monopar Therapeutics (MNPR) over the last 4 years, with Sep 2020 value amounting to $39.5 million.
- Monopar Therapeutics' Enterprise Value rose 978.51% to $39.5 million in Q3 2020 from the same period last year, while for Sep 2020 it was $1.1 million, marking a year-over-year increase of 105.06%. This contributed to the annual value of $222.6 million for FY2024, which is 4300.54% up from last year.
- Per Monopar Therapeutics' latest filing, its Enterprise Value stood at $39.5 million for Q3 2020, which was down 40.88% from $66.8 million recorded in Q2 2020.
- Over the past 5 years, Monopar Therapeutics' Enterprise Value peaked at $159.8 million during Q4 2019, and registered a low of -$10.6 million during Q3 2017.
- Moreover, its 3-year median value for Enterprise Value was -$5.1 million (2019), whereas its average is $25.7 million.
- In the last 5 years, Monopar Therapeutics' Enterprise Value crashed by 240.48% in 2017 and then soared by 2,417.99% in 2019.
- Over the past 5 years, Monopar Therapeutics' Enterprise Value (Quarterly) stood at -$2.9 million in 2016, then tumbled by 240.48% to -$9.8 million in 2017, then grew by 29.54% to -$6.9 million in 2018, then skyrocketed by 2,417.99% to $159.8 million in 2019, then soared by 978.51% to $39.5 million in 2020.
- Its Enterprise Value was $39.5 million in Q3 2020, compared to $66.8 million in Q2 2020 and $63.5 million in Q1 2020.